ERG Rearrangement as a Clonal Expansion Marker for Prostate Cancer

Martin Braun, Roopika Menon, Pavel Nikolov and Sven Perner*

Institute of Pathology, Comprehensive Cancer Center, University Hospital of Tuebingen, Tuebingen, Germany

Abstract: Prostate cancer is the most commonly diagnosed neoplasia and the second most frequent cause of cancer specific death in men in the western civilization. The recent discovery and subsequent characterization of recurrent gene rearrangements of ETS genes – most frequently ERG - in the majority of prostate cancers is a milestone in translational prostate cancer research. In this review we summarize the latest findings on the ERG rearrangement in prostate cancer. In particular, we focused on the relevance of the ERG rearrangement as a marker to elucidate the heterogeneity of prostate cancer, a finding which until recently has been difficult to study. Furthermore, since prostate cancer is a multifocal disease in the majority of cases and it is still poorly understood which tumor focus is responsible for metastasis, we explicate the application of the ERG rearrangement as a prostate cancer specific clonal expansion marker.

Keywords: ERG rearrangement, prostate cancer, gene fusion, clonal expansion marker.

INTRODUCTION

In men, prostate cancer (PCa) is the most frequently observed malign neoplasia in the western world and the second most prevalent cause of cancer-specific death. Nevertheless, for the majority of PCa positive patients the cause of death is not the cancer itself [1].

To estimate the clinical course of PCa, patients PSA-levels, clinical tumor stage, the tumor volume and Gleason-grade in biopsy are commonly used parameters for stratification, which are of particular importance for making clinical decisions and predicting prognosis. However, these parameters are often insufficient for indisputably identifying patients who benefit from treatment. Consequently, it remains a challenge to distinguish between PCa with an aggressive or indolent clinical course. For the most part, this is due to the fact that the molecular biology of the cancerogenesis and progression of PCa is still not fully understood.

To dissect the heterogeneity of the clinical behavior and the molecular pathology of PCa, the development of reliable diagnostic, predictive and prognostic biomarkers is imperative. Promising objects of current PCa biomarker research are the recently identified recurrent gene fusions [2].

THE TMPRSS2-ERG GENE FUSION-A FREQUENT EVENT IN PROSTATE CANCER

The first discovered and best understood cancer-specific gene fusion is the Philadelphia-chromosome in chronic myelogenous leukemia (CML), resulting from a balanced translocation between chromosome 9 and 22 [3]. The translated fusion protein, a tyrosine kinase, which is constitutively active, is responsible for uninhibited proliferation of the tumor cells. Based on the discovery of the Philadelphia chromosome, a targeted therapy has been developed, specifically inhibiting the activity of the tyrosine kinase and thus ameliorating prognosis of CML patients.

Recently, genetic rearrangements resulting in the continuous over expression of potential oncogenes have been found in approximately 50% of PCa in prostatectomy cohorts. The most frequent rearrangement involves the 5’ region of the prostate-specific androgen regulated transmembrane protease serine 2 (TMPRSS2) and members of the erythroblast transformation-specific (ETS) family of transcription factors [2]. Of these, the most common fusion event is the fusion between the ETS member ERG and TMPRSS2. Since the first description of gene fusions in PCa by Tomlins et al. in 2005, a multitude of other gene fusions have been discovered, but occur at much lower frequencies [4]. In most cases, the TMPRSS2-ERG gene fusion is acquired through a deletion of the genetic material between ERG and TMPRSS2, located on 21q. The other mechanism results from an insertion of the ERG gene (Fig. 1) [5].

So far, the TMPRSS2-ERG fusion has been examined in nearly 40 studies with a total number of over 2200 cases. Independent reports conclude that about 50% of PCa samples harbor a fusion between TMPRSS2 and ERG in prostatectomy cohorts [4-16]. Interestingly, in incidentally diagnosed PCa the frequency is as low as 15 to 35%. This may be due to smaller proportion of aggressive PCa cases amongst those [17, 18]. Still, the true reason for the difference in the prevalence rate between prostatectomy cohorts and incidentally diagnosed cohorts remains unknown.

METHODS FOR DETECTION OF THE TMPRSS2-ERG GENE FUSION

There are different ways to detect the TMPRSS2-ERG fusion. On the transcript level, the fusion product can be identified by quantitative or non-quantitative polymerase
Fig. (1). Readout of the ERG break-apart FISH assay. (A) Schematic nucleus without the ERG rearrangement (wild type). A nucleus without the ERG rearrangement shows two yellow signals which indicate the still juxtaposed, differentially labelled centromeric (red) and telomeric (green) regions of ERG. (B) Schematic nucleus with the ERG rearrangement through insertion of one allele. The separated red and green probes indicate the rearrangement of the ERG locus. The non-rearranged allele is indicated by the yellow signal. (C) Schematic nucleus with the ERG rearrangement through deletion of one allele. The disappearance of the green signal in one allele shows the deletion of the telomeric region of ERG. The non-rearranged allele is indicated by the yellow signal.

have assessed the prevalence of ERG rearrangement in the PIN lesions [9, 12, 16]. Approximately 20% of PIN lesions that are in close proximity to an ERG rearranged invasive PCa are also positive for the ERG rearrangement [12, 16]. However, the majority of these cases lack the ERG rearrangement in PIN, even though the adjacent PCa focus harbors the gene fusion. Importantly, if an ERG rearranged PIN lesion is detected in a biopsy, this is evidence for an ERG rearranged invasive PCa focus within the same prostate [12, 16] (Fig. 2A). Together, these findings could be translated into contemporary clinical practice. If exclusively an ERG rearranged PIN lesion is detected by prostate biopsies, but the biopsies do not contain any invasive PCa focus, PCa therapy might be considered without performing further biopsies, based on the fact that an ERG rearranged PIN lesion proves the existence of an ERG rearranged PCa focus within this prostate. Furthermore, these results support the hypothesis that at least subgroups of PIN lesions are true precursors of invasive PCa. On the other hand, it also suggests that most invasive PCa might not originate from PIN.

In a murine model, Klesovitch et al. assessed for the presence of a causal relationship between ERG expression and development/progression of PIN lesions. Notably, ERG over expression resulted in initiation of PIN lesions in this model. A displacement of basal epithelial cells with luminal epithelial cells was observed in these lesions. Subsequently, the luminal cells established direct contact with the stroma cell compartment. The loss of basal cells is known to be a critical milestone in prostate cancerogenesis [25]. Additional PI3K pathway activation further enhanced the initiation of these PIN lesions, King et al. [26]. Likewise, Carver et al. discovered a correlation between ERG over expression in PIN lesions and the loss of function of the tumor suppressor gene PTEN. Remarkably, 93% of fusion positive PIN lesions showed low or no PTEN expression. Studies with murine prostate tissue demonstrated that the ERG rearrangement and the reduced PTEN expression in PIN lesions were associated with a higher incidence of PCa and an increased progression to invasive PCa. An even increased incidence was observed, if the expression of PTEN was significantly reduced in PIN [27]. Together, these results suggest that the ERG rearrangement is not an independent event in PCa. This rear-
rangement cooperates with other genetic aberrations, such as PTEN loss of function, enhancing cancerogenesis and tumor progression.

**ASSESSING ERG REARRANGEMENT STATUS TO STUDY THE PROGRESSION FROM CONVENTIONAL ACINAR PCA TO SMALL CELL PCA**

Small cell cancer of the prostate (SCPC) is a rare but aggressive disease with poor prognosis even if detected in a localized stage. It is poorly understood and controversially discussed as to whether SCPC is an independent tumor entity or just the phenotype of a dedifferentiated acinar PCA [28, 29]. Recently, Scheble et al. assessed a cohort of 15 SCPC for the ERG rearrangement [30]. In agreement with Han et al. they found that the vast majority of SCPC (83%) harbor the ERG rearrangement [31]. Remarkably, if samples contained a transition from conventional acinar PCa into SCPC, both phenotypes harboured the ERG rearrangement (Fig. 2B). Also, the ERG rearrangement has not been found in any cancer of epithelial origin but PCa [32]. Together, these findings suggest that SCPC is related to common acinar PCa and can be seen as a dedifferentiated phenotype of PCa with one common cell of origin.

**ASSESSING ERG REARRANGEMENT STATUS TO IDENTIFY AGGRESSIVE PCA**

Shortly after discovering the ERG rearrangement in PCa, Demichelis et al. observed in a watchful waiting cohort of

---

**Fig. (2).** (A). Schematic of a normal prostatic gland, a PIN lesion, and adjacent acinar PCa with corresponding ERG rearrangement status. The normal prostatic gland (lower right) is not ERG rearranged (illustrated by magnified representative FISH nucleus). The PIN lesion (lower left) and the adjacent acinar PCa (upper part) both harbor the ERG rearrangement (illustrated by magnified representative FISH nuclei). (B) Schematic of a conventional acinar PCa transitioning into small cell PCa with corresponding ERG rearrangement status. Both, the acinar PCa (lower part) and small cell PCa (upper part) harbor the ERG rearrangement (illustrated by magnified representative FISH nuclei).
incidentally diagnosed PCa patients, that patients harboring the ERG rearrangement have a significantly increased prostate cancer-specific death rate [17]. Attard et al. confirmed these results on a similarly designed cohort [18]. About 90% of patients negative for the gene rearrangement survived at least 8 years, whereas those positive for the rearrangement had a statistically significant decreased actuarial survival rate. Amongst those, a subgroup of patients with a duplication of ERG gene faced a worse outcome: only 25% of these patients lived longer than 8 years after initial diagnosis. Also, Nam et al. found on a prostatectomy cohort that the patients with a gene rearrangement had a significantly increased risk of disease recurrence [11]. In addition, Perner et al. showed evidence that the clinical course could also depend on the ERG rearrangement mechanism. ERG rearrangement, through deletion, is associated with higher tumor stage, an increased trend for PSA recurrence, and higher frequency of metastasizing to the pelvic lymph nodes [5]. Observing that all of the assessed metastatic PCa sites containing the ERG rearrangement showed fusion through deletion, Mehra et al. have supported this hypothesis [33].

Controversially, other studies reported an association of the gene rearrangement with clinical features of better prognosis [34, 35]. In cases of clinically localized surgically treated prostate cancers, Gopalan et al. reported an association of ERG rearrangement with lower grade, but no association with stage, biochemical recurrence, metastases, or death [36].

Still, prospective studies are needed to further explore the prognostic relevance of the ERG rearranged PCa on well defined cohorts.

ASSESSING ERG REARRANGEMENT STATUS TO STUDY THE PROGRESSION OF MULTIFOCAL PCA AND METASTATIC DISSEMINATION

In most of the cases, PCa is a multifocal disease with multiple tumor foci arising independently from each other [37]. Noteworthy, morphology, Gleason grade, and size of these different tumor foci can be prevalently heterogenic. A problem in clinical practice is that a needle biopsy often fails to capture all of the foci and may miss the most aggressive tumor focus. Several studies have assessed all foci of multifocal PCa for ERG rearrangement status [21-23]. They have discovered that PCa heterogeneity is also reflected by the ERG rearrangement, i.e., if there are several tumor foci in a prostatectomy sample, each of these harbor an individual fusion status. Interestingly, it was not always the largest tumor focus or the focus with the highest Gleason Grade which harbored the ERG rearrangement (Fig. 3) [38]. Remarkably, the rearrangement status within a specific tumor focus is homogenous on a cell by cell basis. These findings strongly support the hypothesis that multifocal PCa is a heterogeneous disease with each tumor focus deriving from an independent cell of origin.

Moreover, this knowledge could be applied to clinical routine. Since a biopsy does not systematically capture all tumor foci, it is possible that it fails to sample the most aggressive tumor focus. For that reason, a subsequent urine test for the fusion transcript would be helpful to detect missing tumor foci which are missed by biopsies.

From the seeding PCa focus cells are spreading into lymph nodes and/or distant organ sites. Circulating tumor cells (CTCs) - cells that have detached from a tumor focus and have gained access to the angiolymphatic system-- might give rise to the subsequent growth of metastases (Fig. 3). However, it is an ongoing debate, which tumor focus gives rise to metastasis. Often it is assumed that the focus with highest Gleason score or largest tumor volume is metastasizing. But until now, there is no clear evidence for this hypothesis. Commonly used markers like androgen receptor, PTEN, or PSA are inconsistently expressed during metastatic progression, and thus not capable of identifying the originating focus. Even histomorphologic features like Gleason grade might change during progression [39]. Studying the ERG rearrangement status as a marker for clonal expansion gave insight into this issue. As mentioned above, all tumor
cells belonging to a specific focus are homogenous for the ERG rearrangement status. Perner et al. observed in cases with multifocal primary PCa and matched lymph nodes metastasis, that the lymph node metastasis and at least one primary PCa focus was characterized by the same ERG rearrangement status [5, 38]. This underlines that a seeding PCa focus is not necessarily the one with highest Gleason grade or the largest tumor volume, but the one harboring the ERG rearrangement status [5, 38]. In addition, Attard et al. showed that a primary PCa focus and the corresponding isolated CTCs were uniformly characterized by the same ERG rearrangement status - in contrast to a significant heterogeneity of AR and PTEN copy number changes [39].

In conclusion, all of the assessed primary PCa foci and corresponding metastases (regional lymph node, distant metastases, and CTCs) showed homogeneity with regard to the individual ERG rearrangement status. The ERG rearrangement status seems to be a clonal expansion marker that is capable of identifying the seeding tumor focus. The influence of identifying the seeding tumor focus is still underestimated in today’s clinical practice, but may show to have a promising impact soon. Especially with regard to translational research, it will be a huge advantage to be able to identify the metastasizing focus, e.g. to comprehensively study the biology of the seeding focus in order to develop new clinical therapies and biomarkers.

CONCLUSION

The recent discovery and detailed characterization of recurrent gene rearrangements in PCa is a milestone in translational PCa research. A multitude of studies have been working on deciphering the relationship between these gene rearrangements and the clinical heterogeneity of PCa progression. Even though our understanding of these events have been emerging, it is still poorly understood, how exactly these aberration have an effect on this disease.

DISCLOSURES

The Brigham and Women’s Hospital and the University of Michigan have filed a patent on ETS gene rearrangements in prostate cancer, on which Perner is a coinventor, and the University of Michigan have filed a patent on ETS gene rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66(21): 10242-6.


